In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2′,3′-dideoxy-3′-fluoroguanosine

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 3, 2006, Pages 955-961

  Jacquard, A C ^a   Brunelle, M N ^a   Pichoud, C ^a   Durantel, D ^a   Carrouee Durantel S ^a   Trepo, C ^a   Zoulim, F ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXY 3' FLUOROGUANOSINE; ADEFOVIR; GUANOSINE DERIVATIVE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CELL FREE SYSTEM; CELL VIABILITY; CONTROLLED STUDY; CROSS RESISTANCE; DNA STRAND; DNA SYNTHESIS; DRUG MECHANISM; ENZYME ACTIVITY; GENETIC TRANSFECTION; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS RESISTANCE;

ADENINE; ANIMALS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DIDEOXYNUCLEOSIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; DUCKS; HEPATITIS B VIRUS; HEPATITIS B VIRUS, DUCK; HEPATOCYTES; HUMANS; LAMIVUDINE; LIVER NEOPLASMS; MUTATION; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 33644642052     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.3.955-961.2006     Document Type: Article

References (35)

1. Allen, M. I., M. Deslauriers, C. W. Andrews, G. A. Tipples, K. A. Walters, D. L. J. Tyrell, N. Brown, and L. D. Condreay. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
2. Angus, P., R. Vaughan, S. Xiong, H. Yang, W. Delaney, C. Gibbs, C. Brosgart, D. Colledge, R. Edwards, A. Ayres, A. Bartholomeusz, and S. Locarnini. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292-297.
3. Brunelle, M. N., A. C. Jacquard, C. Pichoud, D. Durantel, S. Carrouee-Durantel, J. P. Villeneuve, C. Trepo, and F. Zoulim. 2005. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41:1391-1398.
4. Dannaoui, E., C. Trépo, and F. Zoulim. 1997. Inhibitory effect of penciclovirtriphosphate on duck hepatitis B virus reverse transcription. Antivir. Chem. Chemother. 8:38-46.
5. Delaney, W. E., IV, H. Yang, C. E. Westland, K. Das, E. Arnold, C. S. Gibbs, M. D. Miller, and S. Xiong. 2003. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol. 77:11833-11841.
6. Durantel, D., S. Carrouee-Durantel, B. Werle-Lapostolle, M. N. Brunelle, C. Pichoud, C. Trepo, and F. Zoulim. 2004. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology 40:855-864.
7. Gish, R. G., N. W. Leung, T. L. Wright, H. Trinh, W. Lang, H. A. Kessler, L. Fang, L. H. Wang, J. Delehanty, A. Rigney, E. Mondou, A. Snow, and F. Rousseau. 2002. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob. Agents Chemother. 46:1734-1740.
8. Hafkemeyer, P., A. Keppler-Hafkemeyer, M. Haya, M. von Janta-Lipinski, E. Matthes, C. Lehmann, W. Offensperger, S. Offensperger, W. Gerok, and H. Blum. 1996. Inhibition of duck hepatitis B virus replication by 2′,3′ dideoxy 3′ fluoroguanosine in vitro and in vivo. Antimicrob. Agents Chemother. 40:792-794.
9. Hantz, O., C. Borel, C. Trabaud, F. Zoulim, J. Dessolin, M. Camplo, P. Vlieghe, M. Bouygues, C. Trépo, and J. L. Kraus. 1997. Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles. Antimicrob. Agents Chemother. 41:2579-2581.
10. Hartmann, H., M. W. Vogt, A. G. Durno, M. S. Hirsch, G. Hunsmann, and F. Eckstein. 1988. Enhanced in vitro inhibition of HIV-1 replication by 3′-fluoro-3′-deoxythymidine compared to several other nucleoside analogs. AIDS Res. Hum. Retrovir. 4:457-466.
11. Horwich, A. L., K. Furtak, J. Pugh, and J. Summers. 1990. Synthesis of hepadnavirus particles that contain replication-defective duck hepatitis B virus genomes in cultured HuH7 cells. J. Virol. 64:642-650.
12. Lai, C. L., J. Dienstag, E. Schiff, N. W. Leung, M. Atkins, C. Hunt, N. Brown, M. Woessner, R. Boehme, and L. Condreay. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36:687-696.
13. Lai, C. L., S. G. Lim, N. A. Brown, X. J. Zhou, D. M. Lloyd, Y. M. Lee, M. F. Yuen, G. C. Chao, and M. W. Myers. 2004. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 40:719-726.
14. Lanford, R., L. Notvall, and B. Beames. 1995. Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells. J. Virol. 69:4431-4439.
15. Lanford, R., L. Notvall, H. Lee, and B. Beames. 1997. Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase. J. Virol. 71:2996-3004.
16. Le Guerhier, F., C. Pichoud, S. Guerret, M. Chevallier, C. Jamard, O. Hantz, X. Y. Li, S. H. Chen, I. King, C. Trepo, Y. C. Cheng, and F. Zoulim. 2000. Characterization of the antiviral effect of 2′,3′-dideoxy- 2′,3′-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob. Agents Chemother. 44:111-122.
17. Levine, S., D. Hernandez, G. Yamanaka, S. Zhang, R. Rose, S. Weinheimer, and R. J. Colonno. 2002. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob. Agents Chemother. 46:2525-2532.
18. Lofgren, B., K. Vickery, Y. Y. Zhang, and E. Nordenfelt. 1996. 2′,3′-Dideoxy-3′-fluoroguanosine inhibits duck hepatitis B virus in vivo. J. Viral Hepat. 3:61-65.
19. Marcellin, P., T. T. Chang, S. G. Lim, M. J. Tong, W. Sievert, M. L. Shiffman, L. Jeffers, Z. Goodman, M. S. Wulfsohn, S. Xiong, J. Fry, and C. L. Brosgart. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348:808-816.
20. Ono, S. K., N. Kato, Y. Shiratori, J. Kato, T. Goto, R. F. Schinazi, F. J. Carrilho, and M. Omata. 2001. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Investig. 107:449-455.
21. Peters, M. G., H. Hann, P. Martin, E. J. Heathcote, P. Buggisch, R. Rubin, M. Bourliere, K. Kowdley, C. Trepo, D. Gray, M. Sullivan, K. Kleber, R. Ehrahimi, S. Xiong, and C. L. Brosgart. 2004. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126:91-101.
22. Schroder, I., B. Holmgren, M. Oberg, and B. Lofgren. 1998. Inhibition of human and duck hepatitis B virus by 2′,3′-dideoxy-3′- fluoroguanosine in vitro. Antivir. Res. 37:57-66.
23. Seifer, M., R. Hamatake, M. Bifano, and D. N. Standring. 1998. Generation of replication-competent hepatitis B virus nucleocapsids in insect cells. J. Virol. 72:2765-2776.
24. Seifer, M., R. K. Hamatake, R. J. Colonno, and D. N. Standring. 1998. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother. 42:3200-3208.
25. Seigneres, B., S. Aguesse-Germon, C. Pichoud, I. Vuillermoz, C. Jamard, C. Trepo, and F. Zoulim. 2001. Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo. J. Hepatol. 34:114-122.
26. Seigneres, B., C. Pichoud, P. Martin, P. Furman, C. Trepo, and F. Zoulim. 2002. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 36:710-722.
27. Tavis, J. E., B. Massey, and Y. Gong. 1998. The duck hepatitis B virus polymerase is activated by its RNA packaging signal, epsilon. J. Virol. 72:5789-5796.
28. Tenney, D. J, S. M. Levine, R. E. Rose, A. W. Walsh, S. P. Weinheimer, L. Discotto, M. Plym, K. Pokornowski, C. F. Yu, P. Angus, A. Ayres, A. Bartholomeusz, W. Sievert, G. Thompson, N. Warner, S. Locarnini, and R. J. Colonno. 2004. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob. Agents Chemother. 48:3498-3507.
29. Villeneuve, J. P., D. Durantel, S. Durantel, C. Westland, S. Xiong, C. L. Brosgart, C. S. Gibbs, P. Parvaz, B. Werle, C. Trepo, and F. Zoulim. 2003. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J. Hepatol. 39:1085-1089.
30. Wang, G. H., and C. Seeger. 1992. The reverse transcriptase of hepatitis B virus acts a protein primer for viral DNA synthesis. Cell 71:633-670.
31. Westland, C., W. Delaney IV, H. Yang, S. S. Chen, P. Marcellin, S. Hadziyannis, R. Gish, J. Fry, C. Brosgart, C. Gibbs, M. Miller, and S. Xiong. 2003. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 125:107-116.
32. Xiong, X., C. Flores, H. Yang, J. J. Toole, and C. S. Gibbs. 1998. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28:1669-1673.
33. Zoulim, F. 2004. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antivir. Res. 64:1-15.
34. Zoulim, F., E. Dannaoui, C. Borel, O. Hantz, T.-S. Lin, S.-H. Liu, C. Trépo, and Y.-C. Cheng. 1996. 2′,3′-Dideoxy-β-L-5- fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob. Agents Chemother. 40:448-453.
35. Zoulim, F., and C. Seeger. 1994. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J. Virol. 68:6-13.